Baird maintains Tempus AI at Outperform, raises price target to $92 from $85

Baird upgraded Tempus AI to Outperform and raised its price target to $92 from $85, implying 17.2% upside from the Nov 2 close. Recent analyst targets range from $68 to $100.

Original reporting
Published Nov 3, 2026, 11:54 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 12:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Baird maintains Tempus AI at Outperform, raises price target to $92 from $85 — source image
Decision brief

The 30-second read

Med
01

Why it matters

The price‑target increase may attract short‑term buyers, but without a concrete catalyst the effect could be limited.

02

Market read

A modest analyst upgrade that could generate brief buying pressure in TPUS.

03

What to watch

No new earnings or clinical data were released; the upgrade is based on analyst opinion rather than fresh fundamentals.

Relevance 5/10Novelty 5/10Timing: today

Background

Tempus AI is a U.S. biotech focused on AI‑driven clinical data platforms. Analyst coverage influences its valuation.

Market effects

May lift sentiment in the biotech sector as analysts signal confidence in AI‑driven health platforms.

Primarily U.S. market impact; limited broader regional effect.

Low global relevance beyond niche biotech investors.

Counterpoint

The target raise could be premature if underlying trial data or revenue growth does not meet expectations.

Key entities

  • Baird

    Equity research firm that raised the price target.

  • Tempus AI

    AI‑focused healthcare data company (NASDAQ: TPUS).

Related articles

Med

Tempus CEO Eric Lefkofsky: A Blood Draw Can Catch Returning Cancer 6 to 12 Months Before a Scan

Tempus CEO Eric Lefkofsky reported a record quarter with 23% revenue growth, driven by 32% growth in cancer testing and 33% in data & AI applications. The company signed three $100M+ deals, including with Merck and Bristol Myers Squibb. Tempus claims its blood tests can detect cancer recurrence 6-12 months earlier than scans, leveraging its 600-petabyte data trove and 8,000 hospital integrations. The company is acquiring Personalis to expand into recurrence detection.

$TEMMedAI 8/10

BTIG raises Tempus AI stock price target to $100 on data deals

BTIG raised its price target for Tempus AI (NASDAQ:TEM) to $100, citing strong quarterly results, raised guidance, and significant data deals, including a $200M agreement with Bristol Myers Squibb. The company reported 50% revenue growth and positive adjusted EBITDA. Other analysts also raised price targets, noting strong performance in data and diagnostics segments.

$TEMLow

Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70

Jefferies upgraded Tempus AI (TEM) from Underperform to Hold, raising its price target to $70. The stock, currently at $78.48, has gained 43% in six months. The firm cited strong revenue growth, strategic collaborations, and FDA approval plans. Tempus reported Q3 2026 earnings of $0.07 per share, beating estimates, with revenue up 23% to $411.5 million. Needham raised its price target to $89, citing data business growth.

$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.